Search

CN-121970814-A - Breast milk oligosaccharide compound and application thereof in preparation of composition for improving intestinal canal homeostasis

CN121970814ACN 121970814 ACN121970814 ACN 121970814ACN-121970814-A

Abstract

The invention provides a breast milk oligosaccharide compound and application thereof in preparing a composition for improving intestinal canal homeostasis. The breast milk oligosaccharide compound comprises a bifidobacterium strain, one or more breast milk oligosaccharides, whey proteins and aromatic amino acids, wherein the bifidobacterium strain is selected from bifidobacterium longum or bifidobacterium bifidum, and the aromatic amino acids are selected from phenylalanine or tryptophan. The breast milk oligosaccharide compound promotes the growth of specific probiotics and the generation of aromatic amino acid metabolites, so as to promote the early establishment of intestinal canal homeostasis of infants and reduce the infection risk of infants in the period.

Inventors

  • PENG XIAOYU
  • CHANG SONGLIN
  • YANG QIAO
  • REN JIALI
  • ZHOU WENJING
  • GAO YU
  • Zhou Hanyan
  • WANG JIAQI
  • XIE YU
  • LI WEI
  • PAN LINA

Assignees

  • 澳优乳业（中国）有限公司

Dates

Publication Date
20260505
Application Date
20260202

Claims (10)

  1. 1. A human milk oligosaccharide complex, wherein the human milk oligosaccharide complex comprises a bifidobacterium strain, one or more human milk oligosaccharides, whey proteins and aromatic amino acids, Wherein the Bifidobacterium strain is selected from Bifidobacterium longum (Bifidobacterium longum) or Bifidobacterium bifidum (Bifidobacterium bifidum), and the aromatic amino acid is selected from phenylalanine or tryptophan.
  2. 2. The human milk oligosaccharide formulation of claim 1, wherein the human milk oligosaccharide is selected from the group consisting of 2' -fucosyllactose, 3' -sialyllactose, 6' -sialyllactose, lacto-N-neotetraose, and lacto-N-tetraose.
  3. 3. The breast milk oligosaccharide complex of claim 1 or 2, wherein the bifidobacterium longum is bifidobacterium longum subsp longum (b. Longum subsp. Longum) BB536 and the bifidobacterium bifidum is bifidobacterium bifidum R0071.
  4. 4. A breast milk oligosaccharide formulation according to any of claims 1-3, wherein the breast milk oligosaccharide formulation is a breast milk oligosaccharide formulation 1 comprising bifidobacterium longum subspecies BB536, lactose-N-tetraose, whey protein and phenylalanine, or a breast milk oligosaccharide formulation 2 comprising bifidobacterium bifidum R0071, 2' -fucosyllactose, 3' -sialyllactose, 6' -sialyllactose, lactose-N-neotetraose, lactose-N-tetraose, whey protein and tryptophan.
  5. 5. The human milk oligosaccharide compound according to claim 4, wherein the weight ratio of human milk oligosaccharide, whey protein and phenylalanine in the human milk oligosaccharide compound 1 is 10-85:30-380:2-11, the content of the bifidobacterium strain is 2X 10 6 CFU - 2×10 9 CFU, and the weight ratio of human milk oligosaccharide, whey protein and tryptophan in the human milk oligosaccharide compound 2 is 10-560:60-750:3-24, and the content of the bifidobacterium strain is 2X 10 6 CFU - 2×10 9 CFU.
  6. 6. The human milk oligosaccharide compound according to claim 4, wherein the weight ratio of human milk oligosaccharide, whey protein and phenylalanine in the human milk oligosaccharide compound 1 is 12-80:35-350:2-11, the content of the bifidobacterium strain is 2X 10 7 CFU - 2×10 9 CFU, and the weight ratio of human milk oligosaccharide, whey protein and tryptophan in the human milk oligosaccharide compound 2 is 13-520:70-700:3-22, and the content of the bifidobacterium strain is 2X 10 7 CFU - 2×10 9 CFU.
  7. 7. The human milk oligosaccharide compound of claim 4, wherein the weight ratio of 2' -fucosyllactose, 3' -sialyllactose, 6' -sialyllactose, lactose-N-neotetraose, lactose-N-tetraose in human milk oligosaccharide compound 2 is 45-55:5-10:2-6:3-7:10-15.
  8. 8. Use of a breast milk oligosaccharide complex according to any one of claims 1-7 in the preparation of a composition for improving intestinal homeostasis.
  9. 9. The use according to claim 8, wherein the breast milk oligosaccharide formulation is used to ameliorate intestinal homeostasis problems caused by food allergy.
  10. 10. The use according to claim 8 or 9, wherein the breast milk oligosaccharide complex synergistically promotes intestinal homeostasis by alleviating pathological damage to jejunum tissue, inhibiting pro-inflammatory factor secretion and restoring anti-inflammatory factor secretion, enriching intestinal probiotics.

Description

Breast milk oligosaccharide compound and application thereof in preparation of composition for improving intestinal canal homeostasis Technical Field The invention relates to the field of infant nutrition. In particular, the invention relates to a breast milk oligosaccharide compound and application of the breast milk oligosaccharide compound in preparing a composition for improving intestinal canal homeostasis. Background Early life (first 1000 days), which is a key period for infants to build intestinal homeostasis and establish immune system, and is a key period for various diseases, once the infant intestinal homeostasis is unbalanced, the immune system is disturbed, intestinal diseases such as diarrhea, abdominal pain, inflammatory bowel disease and the like, and allergic diseases such as food allergy, asthma, eczema and the like can be caused. Dietary factors are one of the key factors affecting infant intestinal homeostasis. Breast milk is a well-known source of gold nutrition for infants and infants, and breast milk oligosaccharides (HMOs) exert various functional roles such as directly regulating intestinal immunity, exerting prebiotic effects, etc. from the time when the infant establishes intestinal flora and the immune system to the stage of intestinal homeostasis. In recent years, studies have shown that breast milk oligosaccharides are capable of promoting proliferation of specific bifidobacteria, thereby driving their metabolism of aromatic amino acids to aromatic lactic acid, including indoleacetic acid, phenyllactic acid, and hydroxyphenyllactic acid, etc. The metabolites are used as important intestinal flora-host interaction regulating molecules which are widely focused after short-chain fatty acids, and can play a key role in regulating intestinal immune development in early life through activating signaling pathways such as aromatic hydrocarbon receptor (AhR), hydroxycarboxylic acid receptor 3 (HCA 3) and the like. However, in existing milk-based nutritional compositions, the content and structural diversity of milk oligosaccharides is generally low, which is considered to be one of the important factors that are functionally different from milk. To make up for this gap, there have been studies attempting to combine the prebiotic oligosaccharides with the probiotic bacteria in the relevant products. However, the current research still has obvious limitations that the selected oligosaccharide type and strain range are limited, most of the oligosaccharide type and strain range are based on random selection, and the synergistic effect and the action mechanism of the oligosaccharide type and strain range are not systematically and deeply researched aiming at the oligosaccharide with different structures, so that the effect in practical application cannot reach expectations. Therefore, there is an urgent need for an optimized breast milk oligosaccharide composition that supports the establishment of intestinal homeostasis, so as to overcome the problems of blindness in combination selection, insignificant effect, and the like in the prior art. Disclosure of Invention In view of this, the present invention provides a breast milk oligosaccharide formulation comprising a bifidobacterium animalis strain, one or more breast milk oligosaccharides, whey proteins and aromatic amino acids. Further, another object of the present invention is to provide an application of the breast milk oligosaccharide complex in preparing a composition for improving intestinal canal homeostasis of infants. The composition achieves the effect of improving the intestinal canal steady state of the infants by promoting the growth of specific probiotics in the intestinal canal of the infants and promoting the generation of aromatic amino acid metabolites, namely aromatic lactic acid. In one aspect, the invention provides a breast milk oligosaccharide complex comprising a bifidobacterium strain, one or more breast milk oligosaccharides, whey proteins and an aromatic amino acid, wherein the bifidobacterium strain is selected from bifidobacterium longum (Bifidobacterium longum) or bifidobacterium bifidum (Bifidobacterium bifidum), and the aromatic amino acid is selected from phenylalanine or tryptophan. Alternatively, the breast milk oligosaccharide is selected from the group consisting of 2 '-fucosyllactose (2' -FL), 3 '-sialyllactose (3' -SL), 6 '-sialyllactose (6' -SL), lactose-N-neotetraose (LNnT) or lactose-N-tetraose (LNT). Optionally, the bifidobacterium longum is bifidobacterium longum subsp. Longum (b. Longum subsp. Longum) BB536 and the bifidobacterium bifidum is bifidobacterium bifidum R0071. Optionally, the breast milk oligosaccharide compound is a breast milk oligosaccharide compound 1 comprising bifidobacterium longum subspecies BB536, lactose-N-tetraose, whey protein and phenylalanine, or a breast milk oligosaccharide compound 2 comprising bifidobacterium bifidum R0071, 2' -fucosyllactose, 3' -sialyllactose, 6'